TheraP Clinical Trial Results
A randomised phase II trial of $^{177}$Lu-PSMA-617 THERANOSTIC versus CABAZITAXEL CHEMOTHERAPY

PATIENT SELECTION

MEN WITH PROSTATE CANCER metastatic castration resistant disease

PSMA PET IMAGING shows prostate cancer with PSMA

Patients with high PSMA enter the trial

Positron Emission Tomography (PET) reveals the tracer location with high precision.

$^{68}$Ga-PSMA-11

Progressing after CHEMOTHERAPY Docetaxel

$^{177}$Lu-PSMA-617 THERANOSTICS seamless aligns a diagnostic and therapeutic tracer.

Cancer still progressing Prostate Specific Antigen (PSA) blood analysis: rising and above 20 ng/mL

TRIAL

50% MEN TREATED WITH CABAZITAXEL
20mg/m2 IV q3 weekly
Up to 10 cycles

50% MEN TREATED WITH
$^{177}$Lu-PSMA-617
8.5 GBq IV q6 weekly
0.5 GBq each cycle
Up to 6 cycles

OUTCOMES

PSA Reduction
≥ 50% from baseline

37%
66%

Progression Free Survival at 12 months

3%
19%

Objective Response Rate on CT Scan (RECIST)

24%
49%

Troublesome Adverse Events
Grade 3-4

Diarrhea
53%

Infusion
33%

Patient Reported Outcomes

Dizziness
Skin rash
Hair loss
Insomnia

© Copyright 2023
https://anzup.org.au/thera